Although targeting BACE1 by Verubecestat is not effective for treating AD patients (29), our studies and the fact that this drug is blood-brain barrier penetrant, strongly indicate that it can be repurposed for treatment of BM, highlighting the potential of BACE1 as a novel target for treating lung cancer. Here, BACE1 is linked to lung cancer.